Matthias Mann Lab
@labs_mann
Followers
14K
Following
729
Media
200
Statuses
634
The Mann Lab is a pioneer in mass spectrometry-based proteomics. Tweets represent personal views from lab members and Matthias Mann @MPI_Biochem and @UCPH_CPR.
Munich and Copenhagen
Joined December 2018
Thank you Matthias @labs_mann for your visionary leadership and for creating a scientific family that continues to push boundaries. Congratulations from all members and looking forward to the future! #MS #Proteomics #20Years.
🎉Congratulations to Matthias Mann on 20 years leading Proteomics & Signal Transduction at MPI of Biochemistry! Two decades of groundbreaking mass spectrometry research and training excellent future scientists. #MS #Proteomics #Science @labs_mann
1
7
78
Spatial proteomics & transcriptomics chart #ovariancancer evolution from fallopian tube precursors. Deep Visual Proteomics reveals early SUMOylation, TRIP13 epithelial driver, BGN therapeutic target & epithelial-stromal cooperation in progression.
medrxiv.org
High-grade serous carcinoma (HGSC) is the most common ovarian cancer subtype, typically diagnosed at late stages with poor prognosis. Understanding early molecular events driving HGSC progression is...
0
12
53
RT @MPI_Biochem: Congratulations @MariaWahle on your #PhD🎉. We wish you every success in your future career. @labs_mann @IMPRS_ML
https://….
0
1
0
New preprint reveals why IDO1 inhibitor trials failed! Led by Peter Murray @MPI_biochem, our collaboration discovered IDO1 actually kills ovarian cancer cells via GCN2/ISR pathway - not protecting them. Spatial proteomics uncovers unexpected biology.
biorxiv.org
Indole-2,3-dioxygenase (IDO1) depletes tryptophan to dampen anti-tumor T cells, yet IDO1 inhibitors (IDO1i) have failed clinically. Using deep visual proteomics, we isolated IDO1 high, medium and low...
0
4
32
If you are at the @ASBMB Proteomics conference next week, do attend the session talks and lunch seminars @Absea_bio, @EvosepBio to know about the latest research developments in @labs_mann
Absea’s first lunch seminar at @ASBMB Proteomics is here!. 🗓️ Wed, Aug 20 | 🕧 12:30–2:00 PM | 📍 Broad Institute auditorium.🎙️ Talks by Matthias Mann (Max Planck) & Mikhail Savitski (EMBL). More Information → . Come for the science, stay for the lunch!
0
2
24
ICSB2025 in beautiful Dublin with Systems Biology for Health focus. When: Oct 5-9! .Topics: Cancer, AI/ML, Drug Discovery, Digital Twins, Multi-omics & more.Abstract deadlines:.Oral: Aug 1.Poster: Sep 1.Register: #ICSB2025 #SystemsBiology #Dublin.
icsb2025.com
You can now register for ICSB 2025. Join us at the 24th Annual International Conference on Systems Biology taking place in Dublin this October.
0
0
12
Our collaboration with @ErnstLengyel and team is out in @Nature. The study shows that blocking NNMT reprograms cancer-associated fibroblasts & restores immune response against ovarian cancer. Happy to see that our earlier research contributed to this breakthrough. Congrats all!.
New in @Nature: Drs. @ErnstLengyel, @JannaHeide, @OvCa_UChicago & team discovered a first-of-its-kind NNMT inhibitor that reprograms cancer-associated fibroblasts & restores immune response in ovarian cancer, marking a major step toward better therapies.
0
6
35
Apply today and be part of inspiring science! Deadline July 23rd! #Proteomics #Postdocs.
My lab is hiring a postdoc for translational research in inflammatory skin diseases using cutting-edge proteomics.Join us @MPI_Biochem. All the infos here 🔍 .Apply until July 23. Please RT.
0
6
20
RT @MundAndreas: Excited to share our new preprint! Collaborating with Dr Maitra @Aiims1742 and his outstanding team at @MDAndersonNews an….
0
1
0
Thanks to @UCCancerCenter, @MPI_Biochem @LisaCSchweizer, @hkenny228, @ErnstLengyel, and team for this fantastic collaboration.
0
0
6
#6: Our integrative approach led to validation of 16 therapeutic targets. Combining Milciclib (CDK inhibitor) with Mirvetuximab (targets FOLR1) significantly reduced tumor burden in vivo—a promising new strategy for treating chemo-resistant LGSC.
1
0
3
#5: For clinical interpretation, we performed a multi-modal data integration – ranging from clinical pathology to the molecular fingerprint of each sample.
1
0
3
#4: Spatial mapping of tumor–stroma interactions revealed how epithelial tumor cells engage their environment—highlighting key roles for integrins and fibronectin in facilitating invasion and matrix remodeling.
1
0
3
#3: Our proteomic profiling of epithelial cells revealed several key mechanisms, including the exclusive expression of the brain-specific splicing regulator NOVA in invasive cancer. A molecular ‘switch’ to invasive tumor growth?
1
0
4
#2: Using cell-type resolved #DeepVisualProteomics, we uncovered a gradual transformation from SBT to LGSC, via micropapillary tumors as a transition state—profiling up to 5,400 proteins from just ~200 cells per sample!
1
0
5
#1: Low-grade serous ovarian cancer (LGSC) is a chemo-resistant and metastasizing disease that affects younger women. We studied its origin by analyzing the progression from serous borderline tumors (SBT) across epithelial and stromal cells.
1
0
5
How do non-invasive tumors become invasive? First author Lisa explains below.
1
0
5
Our paper on ovarian cancer #LGSC is out in @Cancer_Cell. Using deep visual proteomics #DVP and spatial transcriptomics, we mapped how non-invasive tumors become deadly ovarian disease, and found a promising new treatment combination.
cell.com
Schweizer et al. profile the tumor progression from non-invasive serous borderline tumors of the ovary to metastatic low-grade serous ovarian cancer. By integrating cell-type resolved Deep Visual...
3
18
81
Congratulations Vincent @_VAlbrecht - well done!.
After many hours in the lab and tackling tricky research questions, it's now time to celebrate. 🥳 Congratulations on your PhD, Vincent @labs_mann. We wish you every success in your future career. @_VAlbrecht
0
1
24